Inclusion Criteria:

- Patients ≥ 18 years and < or = 65 years with an hematological malignancy indicated
for an allogeneic transplantation after reduced intensity conditioning :

- due to the age : for patients between 55 and 65 years.

- or for patients between 18 and 55 years of age presenting a risk of increased
toxicity for myeloablative conditioning (cardiac, renal or pulmonary pathology)

- CML and MPS in blastic phase achieving CR,

- MM stage II or III, relapse after autologous transplant, achieving a response ≥ 30%
or on first line if high risk,

- NHL in 2nd CR, PR after chemotherapy or autologous transplant, chemo-sensible.

- CLL in 2nd CR, PR after chemotherapy or autologous transplant, chemo-sensible.

- AML in 2nd CR or in first line for high risk criteria, secondary AML. In AML, high
risk criteria are defined by : LAM 7, leukocytes>30000/mm3, cytogenetic
abnormalities: t(6,9); 11q23, 17p, 11q, 20q, 21q, -5, del(5q), -7/del7q, del 9q and
inv 3q,

- ALL in 2nd CR or in first line for high risk criteria defined by cytogenetic
abnormalities: 11q23, t(9,22); t(1,19); t(4,11).

- MDS patients without prior chemotherapy

- HLA identical sibling donor

- Performans status < or = 2

- Patients member of a social security company

Exclusion Criteria:

- Age < 18 years or > 65 years

- Pregnant or lactating females

- Known HIV positivity

- Active infectious hepatitis, type A, B or C

- Performance status > 2 according to WHO

- Left ventricular ejection fraction < 40% and Alveolus-capillary diffusion < 50%

- Uncontrollable hypertension with medical therapy

- Creatinine clearance < 60 ml/min

- Hypersensitivity or allergy to psoralen (methoxsalen)

- Disease associated with a photosensitivity

- Hypersensitivity or allergy to both heparin and citrate products

- Contra-indication to Busulfan, Fludarabine, SAT or methotrexate

- Hypersensitivity to ciclosporine, mycophenolate mofetil or mycophenolic acid